leadf
logo-loader
viewZynerba Pharmaceuticals
(
NASDAQ:ZYNE
)

Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting

The posters highlight the company's progress with Zygel, a CBD-based gel for use as a therapy for Fragile X Syndrome

Zynerba Pharmaceuticals - Zynerba Pharmaceuticals Inc presents two posters at the Society of Biological Psychiatry 2021 Virtual Meeting
Both posters will be made available on the Zynerba corporate website at http://zynerba.com/publications/

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. 

Both posters will be made available on the Zynerba corporate website.

The first poster titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]” describes responder thresholds representing individual patient-level changes that the company believes are indicative of meaningful treatment benefit for the ABC-CFXS social avoidance, irritability, and socially unresponsive/lethargic subscales. The poster was presented today (April 29). 

READ: Zynerba Pharmaceuticals says it is fully funded into 2024; lays out plans to advance four Zygel indications in 4Q results

Zynerba said the authors concluded:

  • Responder thresholds for meaningful within-patient behavioral change on key domains of the ABC-CFXS were determined using anchor-based methods based upon US Food and Drug Administration guidance for caregiver-reported outcomes.
  • The responder thresholds for meaningful within-patient behavioral change in CONNECT-FX corresponded to the following reductions: 3 or more points on the ABC-CFXS Social Avoidance subscale; 9 or more points on the ABC-CFXS Irritability subscale; and 5 or more points on the ABC-CFXS Socially Unresponsive/Lethargic subscale.
  • These thresholds serve as a basis for evaluating clinically meaningful treatment effects at the individual patient level in clinical trials of children and adolescents with FXS as demonstrated for Zygel (ZYN2) in CONNECT-FX.
  • Zygel provided meaningful improvements in behavioral symptoms of FXS in patients with ≥90% methylation of the FMR1 gene.

“We believe these data demonstrate the ABC-CFXS subscales capture behaviors that are impactful and meaningful in clinical trials of children with FXS,” said Dr Joseph M. Palumbo, chief medical officer of Zynerba, in a statement. “Therefore, we remain confident that these subscales are fit for purpose for measuring clinical trial endpoints in FXS.”

The second poster titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]” will be presented on April 30 and focuses on the findings in the CONNECT-FX study for the 80% of randomized patients whose FMR1 genes were highly methylated. 

This poster will be presented in Poster Session II beginning at 1 pm ET.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Zynerba Pharmaceuticals

Follow
NASDAQ:ZYNE

Price: 4.35 USD

Market Cap: $179.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read